Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 11251000

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2001 Mar 15
First author
Jassem J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2001 Jul 15;19(14):3441-2. doi: 10.1200/JCO.2001.19.14.3441.
    note
    Source null
    related pmid
    11454896
    relationship
    Comment in

Authors and identifiers

  1. name
    Jassem J
    type
    Author
  2. name
    Pieńkowski T
    type
    Author
  3. name
    Płuzańska A
    type
    Author
  4. name
    Jelic S
    type
    Author
  5. name
    Gorbunova V
    type
    Author
  6. name
    Mrsic-Krmpotic Z
    type
    Author
  7. name
    Berzins J
    type
    Author
  8. name
    Nagykalnai T
    type
    Author
  9. name
    Wigler N
    type
    Author
  10. name
    Renard J
    type
    Author
  11. name
    Munier S
    type
    Author
  12. name
    Weil C
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Jassem J
    type
    Author
  2. name
    Pieńkowski T
    type
    Author
  3. name
    Płuzańska A
    type
    Author
  4. name
    Jelic S
    type
    Author
  5. name
    Gorbunova V
    type
    Author
  6. name
    Mrsic-Krmpotic Z
    type
    Author
  7. name
    Berzins J
    type
    Author
  8. name
    Nagykalnai T
    type
    Author
  9. name
    Wigler N
    type
    Author
  10. name
    Renard J
    type
    Author
  11. name
    Munier S
    type
    Author
  12. name
    Weil C
    type
    Author
bibliography ids
  1. nci-bib-69166432944d3a88075b5bdf
book metadata
content sha256
449be0a19226363ab202c86d7c623bafb3fcb65747264e57aad7d08e4dbe10be
document type
citation
dois
  1. 10.1200/JCO.2001.19.6.1707
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:11251000
immutable id
pubmed:11251000@449be0a19226363ab202c86d7c623bafb3fcb65747264e57aad7d08e4dbe10be
journal
abbreviation
J Clin Oncol
issn electronic
Source null
issn print
0732-183X
issue
6
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1707-15
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2001 Jul 15;19(14):3441-2. doi: 10.1200/JCO.2001.19.14.3441.
    note
    Source null
    related pmid
    11454896
    relationship
    Comment in
outcomes validated
false
pmid
11251000
provenance
batch id
30d2cd7affbbb92b6784
provider
NCBI PubMed ESummary
record sha256
90dea4984e0242f4303ca586bb0d90c59e3b065f104082465d23690d374452ce
response sha256
ae7ed930f8b43c9e34eeae02f278f33f49c15777b81f742392c120eb64949120
retrieved at
2026-09-09T23:45:39.779418+00:00
publication date
display
2001 Mar 15
precision
day
year
2001
publication types
  1. Clinical Trial
  2. Clinical Trial, Phase III
  3. Comparative Study
  4. Journal Article
  5. Multicenter Study
  6. Randomized Controlled Trial
  7. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/11251000/
title
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

Preserved source evidence · Not medical advice